Affiliations 

  • 1 Molecular Genetics Thalassaemia Department, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
  • 2 Laboratory of Medical Genetics, St. Sophia's Children's Hospital, National and Kapodistrian University of Athens, Athens, Greece
  • 3 Department of Haematology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
  • 4 Department of Clinical Genetics/LDGA, Leiden University Medical Center, Leiden, Netherlands
  • 5 School of Medical Sciences, Universiti Sains Malaysia, Malaysia
  • 6 Cyprus School of Molecular Medicine, Nicosia, Cyprus
  • 7 Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences, Hamilton, Canada
Hum Mutat, 2022 Aug;43(8):1089-1096.
PMID: 34510646 DOI: 10.1002/humu.24280

Abstract

Accurate and consistent interpretation of sequence variants is integral to the delivery of safe and reliable diagnostic genetic services. To standardize the interpretation process, in 2015, the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) published a joint guideline based on a set of shared standards for the classification of variants in Mendelian diseases. The generality of these standards and their subjective interpretation between laboratories has prompted efforts to reduce discordance of variant classifications, with a focus on the expert specification of the ACMG/AMP guidelines for individual genes or diseases. Herein, we describe our experience as a ClinGen Variant Curation Expert Panel to adapt the ACMG/AMP criteria for the classification of variants in three globin genes (HBB, HBA2, and HBA1) related to recessively inherited hemoglobinopathies, including five evidence categories, as use cases demonstrating the process of specification and the underlying rationale.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.